Empowering Oncology Decisions
DiagnoCure is a life sciences company that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions.
Special Announcement
2013 Annual General and Special Meeting of Shareholders
News
- May 16, 2013 - DiagnoCure announces presentation on Previstage GCC at the 2013 ASCO annual meeting
- April 29, 2013 - DiagnoCure Directors Re-Elected by Shareholders at Annual and Special Meeting of Shareholders
Events
|
0.27
-0.02
|
Open: 0.27 CAN$.
Quotes are delayed.
|
|
0.27
0.00
|
Open: N/A US$.
Quotes are delayed.
|
Investors
